MAGE-D4 Double Nickase Plasmid (h): sc-418394-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- MAGE-D4 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- MAGE-D4 Double Nickase Plasmid (h) and MAGE-D4 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting MAGED4. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: MAGE-D4/MAGE-D4B Antibody (E-7): sc-393203
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
MAGE-D4 Double Nickase Plasmid (h) | sc-418394-NIC | 20 µg | $410.00 | |||
MAGE-D4 Double Nickase Plasmid (h2) | sc-418394-NIC-2 | 20 µg | $410.00 |
MAGED4 encodes the melanoma antigen family D member 4 (MAGE-D4), a cancer/testis-associated protein implicated in regulation of cellular growth programs and stress-adaptive signaling. MAGE proteins can function as modulators of ubiquitin-dependent protein turnover through interactions with E3 ubiquitin ligases, thereby influencing protein stability, transcriptional control, and cell-cycle progression. Aberrant MAGED4 expression has been reported across multiple tumor types and is frequently studied in the context of oncogenic pathway remodeling, proliferation, and tumor cell fitness. As a human antigen family member, MAGE-D4 is also relevant to investigations of tumor-associated gene expression and immune-related molecular profiling in model systems.
MAGE-D4 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the MAGED4 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within MAGED4. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt MAGED4 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of MAGED4-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.